[Neurohormonal activation in congestive heart failure: does it normalize after heart transplantation?].
OBJECTIVE
In patients with congestive heart failure, neurohormonal activation plays an important role in disease progression and prognosis. The aim of this study was to document the evolution of neurohormonal activation after heart transplantation.


METHODS
Thirty-seven patients on the waiting list for heart transplantation were included in the study. Plasma levels of angiotensin II, aldosterone, endothelin, atrial natriuretic peptide and adrenomedullin were measured before heart transplantation and again 1, 4, 9 and 12 months afterwards. Plasma levels of norepinephrine and renin were measured before and 1 month after heart transplantation.


RESULTS
The levels of angiotensin II, norepinephrine and renin showed a nonsignificant trend towards reduction. The levels of aldosterone were unchanged, and an increase in endothelin levels was seen 9 and 12 months after transplantation. Plasma levels of atrial natriuretic peptide and adrenomedullin were significantly lower 1, 4, 9 and 12 months after heart transplantation compared to pretransplant levels.


CONCLUSIONS
During the first several months after heart transplantation there were no significant reductions in plasma levels of angiotensin II, aldosterone and endothelin, and there were significant reductions soon after surgery in peptides with a predominantly vasodilator effect (atrial natriuretic peptide and adrenomedullin). This unfavorable neurohormonal profile may contribute to the development of posttransplant complications such as edema, arterial hypertension and endothelial dysfunction.
Pérez-Villa
Félix
F
Servicio de Cardiología, Hospital Clínic, Barcelona, Spain. fperez@clinic.ub.es
Roig
Eulalia
E
Ferrer
Elena
E
Cuppoletti
Alfredo
A
Llancaqueo
Marcelo
M
Jiménez
Wladimiro
W
Sanz
Ginés
G
D000328:Adult; D000368:Aged; D000804:Angiotensin II / Q000097:blood / Q000502:physiology; D009320:Atrial Natriuretic Factor / Q000097:blood / Q000502:physiology; D016232:Endothelins / Q000097:blood / Q000502:physiology; D005260:Female; D006333:Heart Failure / Q000097:blood* / Q000503:physiopathology* / Q000601:surgery; D016027:Heart Transplantation / Q000502:physiology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009490:Neurosecretory Systems / Q000502:physiology*; D018377:Neurotransmitter Agents / Q000097:blood / Q000502:physiology; D012084:Renin-Angiotensin System / Q000502:physiology*; D016896:Treatment Outcome; D014662:Vasoconstrictor Agents / Q000097:blood
D016232:Endothelins; D018377:Neurotransmitter Agents; D014662:Vasoconstrictor Agents; D000804:Angiotensin II; D009320:Atrial Natriuretic Factor